Synordia: Withdrawal of the marketing authorisation application


On 7 December 2006, Fournier Laboratories Ireland Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that they wish to withdraw their application for a marketing authorisation for Synordia, for the improvement of glycaemic control and dyslipidaemia in patients with type 2 diabetes.

  • List item

    Questions and answers on the withdrawal of the marketing application for Synordia (PDF/42.41 KB)

    First published: 14/12/2006
    Last updated: 14/12/2006

  • Key facts

    Product number
    Date of withdrawal
    Company making the application
    Fournier Laboratories Ireland Ltd.
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating